Artemis Investment Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $176M | Buy |
3,053,480
+168,182
| +6% | +$9.66M | 1.57% | 11 |
|
|
2026
Q1 | $175M | Buy |
2,885,298
+1,144,545
| +66% | +$66.7M | 1.86% | 9 |
|
|
2025
Q4 | $93.9M | Buy |
+1,740,753
| New | +$83.7M | 1.13% | 25 |
|
|
2025
Q2 | – | Sell |
-242,131
| Closed | -$14.8M | – | 199 |
|
|
2025
Q1 | $14.8M | Buy |
+242,131
| New | +$14.1M | 0.23% | 115 |
|
|
2023
Q3 | – | Sell |
-40,486
| Closed | -$2.59M | – | 205 |
|
|
2023
Q2 | $2.59M | Sell |
40,486
-1,491,822
| -97% | -$100M | 0.03% | 181 |
|
|
2023
Q1 | $106M | Sell |
1,532,308
-351,232
| -19% | -$24.8M | 1.3% | 18 |
|
|
2022
Q4 | $136M | Sell |
1,883,540
-115,421
| -6% | -$8.7M | 1.54% | 15 |
|
|
2022
Q3 | $142M | Buy |
1,998,961
+41,541
| +2% | +$3.01M | 1.62% | 12 |
|
|
2022
Q2 | $151M | Sell |
1,957,420
-28,979
| -1% | -$2.21M | 1.55% | 12 |
|
|
2022
Q1 | $145M | Buy |
+1,986,399
| New | +$133M | 1.16% | 19 |
|
|
2021
Q4 | – | Sell |
-195,224
| Closed | -$11.5M | – | 268 |
|
|
2021
Q3 | $11.5M | Buy |
195,224
+64,214
| +49% | +$4.23M | 0.09% | 182 |
|
|
2021
Q2 | $8.76M | Sell |
131,010
-758,402
| -85% | -$49.5M | 0.08% | 211 |
|
|
2021
Q1 | $56.1M | Sell |
889,412
-111,070
| -11% | -$6.91M | 0.53% | 49 |
|
|
2020
Q4 | $62.1M | Sell |
1,000,482
-40,055
| -4% | -$2.46M | 0.65% | 48 |
|
|
2020
Q3 | $62.7M | Sell |
1,040,537
-176,545
| -15% | -$10.6M | 0.79% | 34 |
|
|
2020
Q2 | $71.8M | Sell |
1,217,082
-596,786
| -33% | -$35.7M | 0.96% | 26 |
|
|
2020
Q1 | $101M | Buy |
1,813,868
+636,863
| +54% | +$38.9M | 0.17% | 13 |
|
|
2019
Q4 | $75.4M | Buy |
1,177,005
+856,705
| +267% | +$49.1M | 0.95% | 29 |
|
|
2019
Q3 | $16.2M | Buy |
320,300
+85,000
| +36% | +$3.99M | 0.22% | 127 |
|
|
2019
Q2 | $10.6M | Sell |
235,300
-252,000
| -52% | -$11.7M | 0.13% | 189 |
|
|
2019
Q1 | $23.3M | Sell |
487,300
-994,581
| -67% | -$49.5M | 0.27% | 108 |
|
|
2018
Q4 | $77M | Buy |
+1,481,881
| New | +$79.6M | 1% | 25 |
|
|
2017
Q4 | – | Sell |
-166,500
| Closed | -$10.6M | – | 225 |
|
|
2017
Q3 | $10.6M | Buy |
166,500
+8,500
| +5% | +$496K | 0.22% | 114 |
|
|
2017
Q2 | $8.8M | Buy |
+158,000
| New | +$8.6M | 0.21% | 113 |
|
|
2016
Q3 | – | Sell |
-98,500
| Closed | -$7.25M | – | 216 |
|
|
2016
Q2 | $7.25M | Buy |
+98,500
| New | +$6.96M | 0.2% | 134 |
|
Other funds holding BMY
Artemis Investment Management's BMY Position: Q2 2026 in Review
Artemis Investment Management increased its Bristol-Myers Squibb (BMY) stake by 5.8% in Q2 2026, buying an estimated $9.66M and bringing the position to 3,053,480 shares worth $176M. The position accounts for 1.57% of the portfolio, ranked #11.
Artemis Investment Management first reported a position in BMY in Q2 2016 and has held it in 25 quarters since. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Artemis Investment Management held 3,053,480 shares of Bristol-Myers Squibb worth $176M as of Q2 2026.
- Artemis Investment Management bought 168,182 Bristol-Myers Squibb shares in Q2 2026, an estimated $9.66M.
- Bristol-Myers Squibb made up 1.57% of Artemis Investment Management's portfolio in Q2 2026, its #11 holding.
- Artemis Investment Management first reported a position in Bristol-Myers Squibb in Q2 2016 and has held it in 25 quarters since.
- 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Artemis Investment Management's 13F filing for Q2 2026, filed 23 Jul 2026.